Cornerstone Therapeutics Announces New Board of...( CARY N.C. Nov. 5 /- Cornerstone T...),Health

CARY, N.C., Nov. 5 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTXD)*, a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today announced that, pursuant to the terms of the recently completed merger between Cornerstone BioPharma Holdings, Inc. and Critical Therapeutics, Inc., Craig A. Collard, 42, president and chief executive officer and a member of Cornerstone BioPharma's board of directors, has been appointed chairman of the board of the newly combined company, Cornerstone Therapeutics, in addition to his position as president and chief executive officer of the combined company. Also, Alastair McEwan, 52, chairman of the board of Cornerstone BioPharma, has been appointed to the board of directors of Cornerstone Therapeutics.

Concurrently, Cornerstone Therapeutics also appointed three independent directors to its board: Christopher Codeanne, 40, Michael Enright, 46, and Michael Heffernan, 43.

"I look forward to working closely with my fellow board members to create a leading specialty pharmaceutical company," said Mr. Collard. "Their diverse financial management and pharmaceutical industry backgrounds will provide us with valuable insight and experience as we continue growing our business."

Mr. Codeanne has served since April 2008 as Chief Operating Officer and Chief Financial Officer of Oncology Development Partners, LLC (d/b/a Oncopartners), a specialized international oncology contract research organization. He served as the Chief Financial Officer of Averion International Corp., a publicly-traded international contract research organization, from December 2006 through April 2008. Prior to Averion, from 2002 through July 2006, Mr. Codeanne was the Chief Financial Officer of SCIREX Corporation LLC, now Premier Research Group plc, an international, full-service clinical research organization. From 1999 to 2002, he was Director of Fina
'/>"/>